Previous 10 | Next 10 |
Summary Europe's economic metrics held up decently in the first half of this year, giving rise to some optimism in regards to the economic fallout from its economic divorce with Russia. Deutsche Bank recently released an estimate for EU 2023 GDP growth of -2.2%. I believe that it ...
Ionis Pharmaceuticals ( NASDAQ: IONS ) said AstraZeneca ( NASDAQ: AZN ) will not advance ION449 (AZD8233) into phase 3 development for hypercholesterolemia after the antisense medicine did show the required efficacy in a phase 2b study. The phase 2b trial, d...
The European Commission (EC) approved the expanded use of AstraZeneca's ( NASDAQ: AZN ) Ultomiris (ravulizumab) as an add-on to standard therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive...
AstraZeneca ( NASDAQ: AZN ) and Merck's ( NYSE: MRK ) Lynparza was approved in China as a maintenance therapy for certain patients with a type of ovarian cancer. Lynparza (olaparib) can now be used as a maintenance therapy for adult patients wit...
Summary Merck's operating income was $5,293 million in Q2 2022, up 37.5% year-over-year. Merck's key medicines have received regulatory approvals from the US and Europe, thereby increasing the number of indications, which will positively affect the company's financial position. ...
If you have $5,000 you can afford to invest in the stock market, now may be a good time to consider doing so, especially if you don't need that money for a while. There are some strong businesses out there that have seen their valuations nosedive this year that could present attractive oppo...
The European Commission (EC) approved AstraZeneca's ( NASDAQ: AZN ) Evusheld to treat people aged 12 years and older with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19. Evusheld is alrea...
Interim results demonstrate statistically significant improvement compared to placebo in hemoglobin levels from baseline to week 12 A prespecified interim analysis of the ALPHA Phase III trial evaluating danicopan (ALXN2040), an investigational, oral factor D inhibitor, ...
AstraZeneca ( NASDAQ: AZN ) said its investigational drug danicopan as an add-on to Ultomiris or Soliris showed positive high-level results in patients with paroxysmal nocturnal haemoglobinuria (PNH) who experience clinically significant extravascular haemolys...
A committee of the European Medicines Agency ( EMA ) recommended the approval of AstraZeneca ( NASDAQ: AZN ) and Sanofi's ( NASDAQ: SNY ) antibody Beyfortus in EU to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in new...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
First BTK inhibitor to show favorable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in comb...
The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate...
New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Socie...